Thyrotoxicosis with pegylated interferon alfa-2b.
BACKGROUND: Despite adequate surgery, a diagnosis of stage III melanoma carries a high risk of relapse, and hence mortality. Interferon alfa is the only treatment that has currently been shown to alter the natural history of the disease, delaying relapse-free survival, particularly in patients with...
Huvudupphovsmän: | Lowndes, SA, Asher, R, Middleton, MR |
---|---|
Materialtyp: | Journal article |
Språk: | English |
Publicerad: |
2010
|
Liknande verk
Liknande verk
-
Efficacy of pegylated interferon alfa-2b «Algeron» in the treatment of chronic hepatitis C
av: M. V. Mayevskaya, et al.
Publicerad: (2013-03-01) -
Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C
av: T Kanda, et al.
Publicerad: (2011-03-01) -
Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma
av: Dong-Dong Jia, et al.
Publicerad: (2021-06-01) -
Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents
av: Jaber Al Ali, et al.
Publicerad: (2010-04-01) -
HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b
av: Hui Ma, et al.
Publicerad: (2016-01-01)